MediWound
MediWound is a commercial and clinical-stage biotechnology company developing bromelain-based enzymatic therapies for non-surgical burn and chronic wound debridement. Its approved product NexoBrid is marketed in over 40 countries, while EscharEx is in Phase III development for chronic wounds.
- Company typePublic
- Founded2001
- HeadquartersYavne, Israel
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What MediWound does
MediWound Ltd. is a fully integrated biotechnology company founded in 2001 and headquartered in Yavne, Israel, listed on NASDAQ under the ticker MDWD. It develops and commercializes next-generation enzymatic therapies for non-surgical tissue repair, focused on two products built on a proprietary bromelain-based platform derived from pineapple plant stems. NexoBrid, an FDA-, EMA-, and PMDA-approved orphan biological drug, selectively removes eschar in deep partial- and full-thickness thermal burns for adult and pediatric patients and is marketed in over 40 countries. EscharEx, the second platform product, is a bioactive enzymatic therapy in Phase III development for debridement of chronic and hard-to-heal wounds (venous leg ulcers, diabetic foot ulcers, pressure ulcers).
The company operates a vertically integrated model spanning R&D, cGMP-certified aseptic manufacturing (recently expanded to sixfold prior capacity), and global commercialization. In the United States, NexoBrid is sold through an exclusive partnership with Vericel Corporation, which also holds the BARDA procurement contract. In Europe, MediWound runs direct sales supplemented by PolyMedics Innovations for the DACH region, with additional distribution partners in Japan and Australia. The revenue mix blends commercial product sales with substantial non-dilutive funding: a BARDA contract worth up to $197 million over ten years, $14.4 million in cumulative U.S. Department of Defense funding for a temperature-stable military formulation, and a €16.25 million European Innovation Council award supporting EscharEx development.
Management is led by CEO Ofer Gonen (former CEO of Clal Biotechnology Industries), with a board chaired by Nachum Shamir (former CEO of Given Imaging and Luminex). MediWound has treated over 16,000 patients worldwide and operates from offices in Israel, Germany, the United States, and five additional European countries. FY2025 revenue was $17.0 million, down from $20.2 million in 2024 due to U.S. government procurement delays, while management guides to $24–26 million in 2026 and $50–55 million by 2028.
MediWound firmographics
Firmographics- Name
- MediWound
- Legal name
- MediWound Ltd.
- Website
- http://mediwound.com
- Company type
- Public
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- MediWound is a commercial and clinical-stage biotechnology company developing bromelain-based enzymatic therapies for non-surgical burn and chronic wound debridement. Its approved product NexoBrid is marketed in over 40 countries, while EscharEx is in Phase III development for chronic wounds.
- Ownership category
- akta.pro rank
MediWound industry classification
Industry- Product category
- Enzymatic Wound Care Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)
- akta.pro secondary industries
- Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE), Wound Care & Ulcer Management (HLAKACAN)
Keywords
Where MediWound is headquartered
LocationHeadquarters
- HQ city
- Yavne
- HQ country
- Israel
- HQ region
- Middle East
Offices8 records
Markets served
MediWound business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Revenue model
- Product Sales (NexoBrid): Revenue generated from sales of FDA/EMA/PMDA approved NexoBrid for burn eschar removal, marketed in over 40 countries through direct sales and distribution partnerships.
- Government Contracts (BARDA/DoD): Non-dilutive funding from U.S. government agencies including BARDA contract worth up to $197 million for NexoBrid procurement and development, and DoD funding for temperature-stable formulation development ($18.2 million disclosed for room-temperature stable formulation).
- European Innovation Council Funding: €16.25 million funding from EIC to support EscharEx development for diabetic foot ulcers, including €2.5 million grant component, aimed at accelerating market introduction by four years.
- Strategic Partnership Revenue: $25 million private placement financing from Mölnlycke Health Care to fund development and commercialization activities, strengthening strategic partnership in wound care solutions.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels4 records
MediWound product offering
Product offeringCore offering
MediWound develops and commercializes proprietary bromelain-based enzymatic therapeutics for non-surgical tissue repair. Its commercial product NexoBrid is an FDA, EMA, and PMDA approved orphan biological drug for enzymatic eschar removal in deep partial and full-thickness thermal burns, marketed in over 40 countries. Its pipeline product EscharEx is a Phase III bioactive enzymatic therapy for debridement of chronic, hard-to-heal wounds including venous leg ulcers, diabetic foot ulcers, and pressure ulcers.
Product overview
MediWound is a fully integrated biotechnology company developing next-generation enzymatic therapeutics for non-surgical tissue repair. The company operates two core products: NexoBrid®, an FDA/EMA/PMDA approved orphan biologic for burn eschar removal currently marketed in over 40 countries, and EscharEx®, a Phase III pipeline drug for chronic wound debridement targeting venous leg ulcers, diabetic foot ulcers, and pressure ulcers. Both products are based on a proprietary platform technology using proteolytic enzymes enriched in bromelain derived from pineapple plant stems. The company maintains vertically integrated capabilities spanning R&D, manufacturing (cGMP-certified facility), and global commercialization through partnerships.
Differentiator
Problem solved
Functional benefit
Brands
- NexoBrid: FDA, EMA and PMDA approved orphan biological drug for eschar removal in deep partial and full-thickness thermal burns for adults and pediatric patients
- EscharEx
Products and services
- NexoBrid FDA, EMA, and PMDA approved orphan biological drug for enzymatic removal of eschar in patients with deep partial- and full-thickness thermal burns. Selectively removes non-viable tissue while preserving viable tissue. Approved for use in adults and pediatric patients in over 40 countries including the United States, European Union, and Japan.
- EscharEx Bromelain-based, bioactive enzymatic therapy in advanced clinical development for debridement of chronic and hard-to-heal wounds. Designed for topical, once-daily application with demonstrated favorable safety profile and effective wound bed preparation in multiple Phase II trials. Global Phase III study in venous leg ulcers underway; DFU trial planned for H2 2026; PU IIT planned for H2 2026.
Quantifiable outcome
- Over 16,000 patients treated worldwide with NexoBrid
- +3 more outcomes
Companies that use MediWound
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles3 records
MediWound technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
MediWound partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered minor, strategic and core.
- B. BraunminorB. Braun joined MediWound's clinical development program as research collaborator for diabetic foot ulcer (DFU) study, supporting Phase II clinical trial preparation planned for H2 2026.
- PolyMedics Innovations GmbHstrategicNovember 2024 partnership to expand NexoBrid distribution across Europe. PolyMedics serves as promotional partner in DACH region while supporting broader European market access.
- Vericel CorporationcoreStrategic partnership for U.S. commercialization of NexoBrid. Vericel holds BARDA contract for government procurement and development activities. Company markets NexoBrid in the United States for burn eschar removal.
Scale indicators16 records
Recent moves6 records
Expansion highlights6 records
MediWound competitors and assessment
Company assessmentDirect peers
- Vericel Corporation: Vericel is MediWound's US commercialization partner for NexoBrid and holds the BARDA stockpile contract. Vericel also commercializes MACI and Epicel in the regenerative medicine space, making it both a commercial partner and a strategic comparable in cell-based and biologic wound/orthopedic therapies.
- Organogenesis Holdings: Organogenesis is a regenerative medicine company specializing in skin substitutes and wound care biologics (Apligraf, Dermagraft). It competes directly with MediWound's bromelain enzymatic platform in the chronic wound healing market, particularly for venous leg ulcers and diabetic foot ulcers.
- MiMedx Group: MiMedx develops and commercializes regenerative biologics (EpiFix, AmnioFix) for wound care and surgical recovery. It competes with NexoBrid and EscharEx in the advanced wound care biologics space and serves similar hospital and outpatient wound care channels.
Broad incumbents
- Mölnlycke Health Care: Mölnlycke is a global leader in advanced wound care (Mepilex, Mepitel) and made a $25M strategic investment in MediWound. As a major incumbent in the same wound care end-market, Mölnlycke represents both a partner and a benchmark for scaled wound care commercialization.
- Smith & Nephew: Smith & Nephew's Advanced Wound Management portfolio competes with NexoBrid/EscharEx in the broader wound debridement and healing space. As a large diversified medtech incumbent, it represents the scale benchmark MediWound aims to compete against as it expands into chronic wound indications.
- Integra LifeSciences: Integra LifeSciences acquired Derma Sciences in 2017 and competes directly in advanced wound care with skin substitutes and regenerative products. MediWound board member Stephen Wills previously served as Executive Chairman of Derma Sciences, highlighting direct competitive and personnel overlap.
- ConvaTec Group: ConvaTec is a major global wound care company offering advanced dressings, hydrocolloids, and debridement products across chronic and acute wound markets. It is a key incumbent peer for MediWound's planned expansion into diabetic foot ulcers and venous leg ulcers with EscharEx.
- Coloplast: Coloplast's Wound & Skin Care division offers a broad portfolio of dressings and wound management products across chronic wound indications including DFUs and VLUs. As a European medtech incumbent with similar chronic wound focus, it represents a relevant commercial benchmark for MediWound's EscharEx pipeline.
Peers
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Customer concentration
MediWound social profiles
Digital presenceMediWound compliance and trust
Trust signalCompliance4 records
MediWound financial estimates
Financial estimateRevenue estimate
Valuation estimate
MediWound leadership team
Management profileNumber of profiles
Profiles16 records
MediWound funding detail
Funding detailFunding overview
Funding rounds12 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MediWound M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MediWound
What does MediWound do?
MediWound develops and commercializes proprietary bromelain-based enzymatic therapeutics for non-surgical tissue repair. Its commercial product NexoBrid is an FDA, EMA, and PMDA approved orphan biological drug for enzymatic eschar removal in deep partial and full-thickness thermal burns, marketed in over 40 countries. Its pipeline product EscharEx is a Phase III bioactive enzymatic therapy for debridement of chronic, hard-to-heal wounds including venous leg ulcers, diabetic foot ulcers, and pressure ulcers.
Is MediWound a public or private company?
MediWound is a public company. It is classified as public and is currently operating.
When was MediWound founded?
MediWound was founded in 2001. It employs 101 to 250 people.
Where is MediWound based?
MediWound is headquartered in Yavne, Israel, in the Middle East region.
How does MediWound make money?
Four revenue lines are on record. Product Sales (NexoBrid) is the primary driver. The others are government Contracts (BARDA/DoD), european Innovation Council Funding and strategic Partnership Revenue.
Who are MediWound's main competitors?
Direct peers on record are Vericel Corporation, Organogenesis Holdings and MiMedx Group. Broad incumbents are Mölnlycke Health Care, Smith & Nephew, Integra LifeSciences, ConvaTec Group and Coloplast. PolyMedics Innovations (PMI) is listed as a peer.
Does MediWound have an API?
No public API is recorded for MediWound.
What industry is MediWound in?
MediWound's product category is Enzymatic Wound Care Therapeutics. Its primary akta.pro industry code is HLAAAGAG, Wound Healing & Skin Regeneration (advanced dressings, skin substitutes), with a secondary code of HLAHALAE, Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts). Its NAICS code is 325414 and its SIC code is 2836.